Company Encyclopedia
View More
name
NKY
300109.SZ
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, oral care, and household care; alcohol, soft drinks, and food; battery, petroleum and natural gas, and photovoltaic; and membrane, textile and dyeing, agriculture, stationery, semiconductor, and other industries.
3.134 T
300109.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Commodity ChemicalsIndustry
Industry Ranking137/271
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.63%C
    • Profit Margin16.56%A
    • Gross Margin44.85%B
  • Growth ScoreD
    • Revenue YoY-2.76%D
    • Net Profit YoY-40.02%D
    • Total Assets YoY-1.43%D
    • Net Assets YoY5.86%B
  • Cash ScoreC
    • Cash Flow Margin604.04%C
    • OCF YoY-2.76%D
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio13.01%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NKY released its performance for the first three quarters, with a net profit attributable to the parent company of 201 million yuan, a decrease of 35.39%

    According to the Zhitong Finance APP, NKY released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 951 million yuan, a year-on-year decrease of 14.36%. The net profit attributable to shareholders of the listed company was 201 million yuan, a year-on-year decrease of 35.39%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 182 million yuan, a year-on-year decrease of 43.50%. The basic earnings per share were 0.41 yuan

    Zhitong·
    SZ
    300109
    +0.69%
    Zhitong·
    SZ
    300109
    +0.69%

    NKY released its performance for the first half of the year, with a net profit attributable to the parent company of 139 million yuan, a decrease of 34.74%

    According to the Zhitong Finance APP, NKY released its 2025 semi-annual report, showing an operating income of 644 million yuan, a year-on-year decrease of 12.36%. The net profit attributable to shareholders of the listed company was 139 million yuan, a year-on-year decrease of 34.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 129 million yuan, a year-on-year decrease of 40.76%. The basic earnings per share were 0.29 yuan

    Zhitong·
    SZ
    300109
    +0.69%
    Zhitong·
    SZ
    300109
    +0.69%

    NKY: The company's PVP products have not yet been directly supplied to relevant robotics companies

    NKY stated on the interactive platform that, as of now, the company's PVP products have not been directly supplied to relevant robotics companies. Regarding the application of PVP in electronic skin, the company will continue to actively expand downstream potential demand based on its performance advantages

    Zhitong·
    SZ
    300109
    +0.69%
    Zhitong·
    SZ
    300109
    +0.69%

    NKY director Zhao Wei received an administrative penalty decision from the Henan Securities Regulatory Bureau

    Zhao Wei, a director of NKY, received an administrative penalty decision from the Henan Securities Regulatory Bureau due to his son's short-term trading during his tenure. Zhao Wei's son sold 1,285,500 shares of NKY between July 9 and December 19, 2024, amounting to 22,330,480 yuan, and bought 238,500 shares, amounting to 3,867,640 yuan. This behavior violated the Securities Law, and Zhao Wei was warned and fined 300,000 yuan

    Zhitong·
    SZ
    300109
    +0.69%
    Zhitong·
    SZ
    300109
    +0.69%

    NKY: The invested company for injectable human interleukin-2 has been approved for clinical use

    NKY announced that its investee company, Beijing Liangyuan Biopharmaceutical Research Co., Ltd., has obtained implied approval for domestic clinical trials of its injectable human interleukin-2, indicated for advanced solid tumors. This product is the first globally to be developed using a high-affinity hierarchical assembly technology platform and is a new drug targeting various solid tumors, originating from China. The company holds a 23.8095% stake in Liangyuan Biopharmaceutical, and this research and development progress is beneficial for consolidating the company's first-mover advantage in the precision medicine field and enhancing its core competitiveness

    Zhitong·
    SZ
    300109
    +0.69%
    Zhitong·
    SZ
    300109
    +0.69%
    © 2025 Longbridge｜Disclaimer